News

Following the approval of the investigational new drug (IND) application, Diamyd plans to initiate a Phase I clinical study. The trial will be designed as a dose-escalation study

The company has said that the clinical trial successfully met all objectives and that BIO 300 was well tolerated at all dose levels which were studied. The completion

Breckenridge has completed a shared 180-day exclusivity period and will immediately launch oxcarbazepine tablets 150mg, 300mg, and 600mg. Oxcarbazepine tablets are AB rated to Trileptal which is being

Ranaz has acquired all outstanding shares of Bar Tech, which were held by four shareholders, in exchange for 738,673 common shares and 369,337 warrants. Each Warrant entitles its

Nucleonics plans to enroll a total of 15 patients infected with hepatitis B virus (HBV) with mild to moderate disease and no evidence of cirrhosis at three US

A consolidation of existing shares has taken place and additional shares will be issued as consideration for the merger. As a result of this merger, it is anticipated

One of these clinical trials did not meet its primary endpoint of demonstrating a statistically significant reduction in patients’s pain intensity levels over 48 hours compared to placebo,

This patent application represents a very significant move strategically for Solagran. It constitutes the first step towards changing the status of Bioeffective(r) A from a complementary medicine substance,

Alder plans to use the financing to advance its lead programs through human clinical trials and to continue to advance its proprietary Mab Xpress yeast antibody production technology.